| Target |
GCP/IL-8 protein II, MDNCF, IL8/NAP1 form III, IL-8(1-77), Neutrophil-activating factor, GCP/IL-8 protein I, GCP/IL-8 protein VI, Interleukin-8, Chemokine (C-X-C motif) ligand 8, Neutrophil-activating protein 1, Monocyte-derived neutrophil chemotactic factor, (Ser-IL-8)72, MDNCF-b, LYNAP, GCP/IL-8 protein V, IL8/NAP1 form IV, MONAP, IL8/NAP1 form V, IL8/NAP1 form VI, NAP-1, Granulocyte chemotactic protein 1, GCP/IL-8 protein III, IL8/NAP1 form II, IL8, IL-8, CXCL8, IL8/NAP1 form I, (Ala-IL-8)77, Protein 3-10C, GCP/IL-8 protein IV, Emoctakin, GCP-1, C-X-C motif chemokine 8, NAF, T-cell chemotactic factor, MDNCF-c, Monocyte-derived neutrophil-activating peptide, Lymphocyte-derived neutrophil-activating factor |
| Function |
InVivoMAb Anti-Human IL8/CXCL8 (Iv0023)[Iv0023] (ARO-A13356) is amouse monoclonalantibody detectingGCP/IL-8 protein II, MDNCF, IL8/NAP1 form III, IL-8(1-77), Neutrophil-activating factor, GCP/IL-8 protein I, GCP/IL-8 protein VI, Interleukin-8, Chemokine (C-X-C motif) ligand 8, Neutrophil-activating protein 1, Monocyte-derived neutrophil chemotactic factor, (Ser-IL-8)72, MDNCF-b, LYNAP, GCP/IL-8 protein V, IL8/NAP1 form IV, MONAP, IL8/NAP1 form V, IL8/NAP1 form VI, NAP-1, Granulocyte chemotactic protein 1, GCP/IL-8 protein III, IL8/NAP1 form II, IL8, IL-8, CXCL8, IL8/NAP1 form I, (Ala-IL-8)77, Protein 3-10C, GCP/IL-8 protein IV, Emoctakin, GCP-1, C-X-C motif chemokine 8, NAF, T-cell chemotactic factor, MDNCF-c, Monocyte-derived neutrophil-activating peptide, Lymphocyte-derived neutrophil-activating factorinELISA, FCM, Neutralization. Suitable forHuman.HighlightsProtein A/G purified from cell culture supernatant.— Ensuring high specificity and minimal background.Multi-Application— Validated across multiple applications. |
